A speculative solar play and a conservative bank both rank as top contrarian buys for the new year.
These two favorites are each focused on new biotech drug development projects.
This Canadian energy company offers an 8.7% yield and capital gains potential.
The big financial story this year could be a rebound in the troubled eurozone.
Following the mortgage meltdown, this firm is now positioned for on ongoing turnaround.
Prospects for these funds are boosted by their top-ranked managers.
This biotech is moving into the fast-growing market known as biosimilars.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The retailer labels the character's fake memoir as non-fiction. This comes weeks after it categorized the the Bible as fiction.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Preteens, rejoice. The grown-ups have a compelling reason to consider getting you a tablet this year. Adults, listen up.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.